Per accedir als documents amb el text complet, si us plau, seguiu el següent enllaç: http://hdl.handle.net/2445/61823

Títol:	Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response
Autor/a:	Fonseca, Francina; Torre Fornell, Rafael de la; Díaz, Laura; Pastor Bosch, Antonio; Cuyàs, Elisabet; Pizarro Lozano, Nieves; Khymenets, Olha; Farré Albaladejo, Magí; Torrens, Marta
Altres autors:	Universitat de Barcelona
Abstract:	Although the efficacy of methadone maintenance treatment (MMT) in opioid dependence disorder has been well established, the influence of methadone pharmacokinetics in dose requirement and clinical outcome remains controversial. The aim of this study is to analyze methadone dosage in responder and nonresponder patients considering pharmacogenetic and pharmacokinetic factors that may contribute to dosage adequacy. Opioid dependence patients (meeting Diagnostic and Statistical Manual of Mental Disorders, [4th Edition] criteria) from a MMT community program were recruited. Patients were clinically assessed and blood samples were obtained to determine plasma concentrations of (R,S)-, (R) and (S)- methadone and to study allelic variants of genes encoding CYP3A5, CYP2D6, CYP2B6, CYP2C9, CYP2C19, and P-glycoprotein. Responders and nonresponders were defined by illicit opioid consumption detected in random urinalysis. The final sample consisted in 105 opioid dependent patients of Caucasian origin. Responder patients received higher doses of methadone and have been included into treatment for a longer period. No differences were found in terms of genotype frequencies between groups. Only CYP2D6 metabolizing phenotype differences were found in outcome status, methadone dose requirements, and plasma concentrations, being higher in the ultrarapid metabolizers. No other differences were found between phenotype and responder status, methadone dose requirements, neither in methadone plasma concentrations. Pharmacokinetic factors could explain some but not all differences in MMT outcome and methadone dose requirements.
Matèries:	-Metadona -Farmacocinètica -Metabolisme dels medicaments -Citocrom P-450 -Resistència als medicaments -Proteïnes de membrana -Polimorfisme genètic -Methadone hydrochloride -Pharmacokinetics -Drugs metabolism -Cytochrome P-450 -Drug resistance -Membrane proteins -Genetic polymorphisms
Drets:	cc-by (c) Fonseca, Francina et al., 2011 http://creativecommons.org/licenses/by/3.0/es
Tipus de document:	Article Article - Versió publicada
Publicat per:	Public Library of Science (PLoS)
Compartir:

Mostra el registre complet del document